To provide an updated view on the role of cell-free DNA as a predictor of pathological response to neoadjuvant therapy in patients with muscle-invasive bladder cancer.
A systematic review was conducted from September 2023 to October 2023.
Selected studies from the MEDLINE and clinical trial databases were critically analyzed regarding the clinical efficacy of cell-free DNA as a predictive instrument after neoadjuvant therapy in bladder cancer. The methodological quality assessment was based on the QUADAS-2 tool.
In this systematic review, we analyzed 5 studies encompassing a cumulative patient cohort of 780 individuals diagnosed with muscle-invasive bladder cancer, with a median follow-up ranging from 6 to 23 months. Among these studies, 4 primarily focused on detecting and analyzing circulating tumor DNA in plasma, while 1 study uniquely utilized cell-free tumor DNA in urine samples. The diagnostic accuracy of cell-free DNA in plasma ranges from 79% to 100%, indicating a variable yet significant predictive capability. In contrast, the study utilizing urinary cell-free DNA demonstrated an accuracy of 81% in predicting treatment response post-neoadjuvant chemotherapy.
Cell-free DNA is emerging as a valuable biomarker for predicting response to neoadjuvant chemotherapy in patients with muscle-invasive bladder tumors.
Clinical genitourinary cancer. 2024 Apr 06 [Epub ahead of print]
Caio V Suartz, Lucas Motta Martinez, Maurício D Cordeiro, Luiz A A Botelho, Fábio P Gallutti, José M Mota, Katia R M Leite, Paul Toren, William C Nahas, Leopoldo A Ribeiro-Filho
Division of Urology, Institute of Cancer of São Paulo, University of São Paulo, Brazil; Division of Urology, Department of Surgery, CHU de Québec - Université Laval, Quebec City, QC, Canada. Electronic address: ., Division of Urology, Institute of Cancer of São Paulo, University of São Paulo, Brazil., Genitourinary Medical Oncology Service, Institute of Cancer of São Paulo, University of São Paulo, Brazil., Laboratory of Medical Investigation (LIM55), Urology Department, University of Sao Paulo Medical School, Sao Paulo, Brazil., Division of Urology, Department of Surgery, CHU de Québec - Université Laval, Quebec City, QC, Canada.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/38688207